Top Links

Articles Related to pharmaceuticals

A Review on Veterinary Medical Waste Disposal and Management

The purpose of this review is to highlight environmentally sound disposal methods of veterinary pharmaceutcals wastes and the risks associated with its improper disposal, with a systematic review. Pharmaceuticals are produced and used in large volumes increasingly every year throughout the world. Medicinal waste products are medicinal products which are not fit for sale or supply. Waste produced in veterinary practice in common with other medical disciplines can be broken down into general waste similar to household waste, clinical waste and hazardous waste. Disposal of pharmaceutical compounds is becoming a complex environmental issue. The safety and health of the environment is directly affected by the disposal methods. Improper medical waste disposal and management causes all types of pollution (air, soil, and water). Proper waste management have to be undertaken to ensure that it does not affect the environment and not cause health hazards to the people living there. Different types of medical waste require different disposal techniques. The appropriate safe disposal method recommended will depend principally on the pharmaceutical dosage form of the drugs. One of the best advisable veterinary waste disposal practices is to store the waste properly before collection and transportation. Some general medical waste can be disposed of in landfill, others require specialist treatment such as a medical incinerator. Appropriate safety precautions, which minimize the risk to the health and safety of pharmacy staff, should be taken when handling medicinal waste products. Extra precautions should be taken by staff in high-risk groups as they may be at increased risk if they come into contact with particular substances. The cost of pharmaceuticals waste disposal comprises of direct costs of supplies and materials used for collection, transport, storage, treatment, disposal, decontamination and cleaning, the cost of labor and material for training and maintenance, and will vary depending on the treatment method chosen, the capacity of the treatment facility and according to the waste quantity and quality.
View complete article: PDF  |  Full-text

Pharmacokinetics, Biotransformation, Distribution and Excretion of Empagliflozin, a Sodium-Glucose Co-Transporter (SGLT 2) Inhibitor, in Mice, Rats, and Dogs

The metabolism, pharmacokinetics, excretion and distribution of a sodium-glucose co-transporter (SGLT 2) inhibitor, empagliflozin, were studied in mice, rats and beagle dogs following a single oral or intravenous administration of [14C]-empagliflozin. Empagliflozin was well absorbed in all species after oral administration.
View complete article: PDF  |  Full-text

Croscarmellose Sodium Efficiency in the Development of a Generic Capsule Formulation of Piroxicam, Comparable Dissolution Profile to the Innovator Product, Feldene

The objective of this study was to evaluate the encapsulation performance of Croscarmellose sodium, a superdisintegrant in a low-dose, poor-solubility drug formulation and the in-vitro dissolution performance of the Piroxicam capsules. Preparation, characterization and evaluation of the effects of the different concentrations of carmellose sodium and the amount of dried starch on in-vitro dissolution of Piroxicam capsules. Piroxicam was chosen for its very low solubility in biological fluids, which result in poor systemic bioavailability after oral administration. Piroxicam can be categorized as Class II drugs according to the Biopharmaceutics Classification System.
View complete article: PDF  |  Full-text

Anti-Arthritic Efficacy And Safety Of Crominex 3+ (Trivalent Chromium, Phyllanthus emblica Extract, And Shilajit) In Moderately Arthritic Dogs

The present investigation was undertaken to evaluate the therapeutic efficacy and safety of Crominex 3+ (a complex of trivalent chromium, Phyllanthus emblica (Amla) extract and purified Shilajit) in moderately arthritic dogs.
View complete article: PDF  |  Full-text  | Digital
 
 

Anti-Inflammatory and Anti-Arthritic Efficacy and Safety of Purified Shilajit in Moderately Arthritic Dogs

The objective of this investigation was to evaluate the efficacy and safety of purified Shilajit in moderately arthritic dogs. Ten client-owned dogs in a randomized double-blinded study received either a placebo or Shilajit (500 mg) twice daily for a period of five months. Dogs were evaluated each month for physical condition (body weight, body temperature, heart rate, and respiration rate) and pain associated with arthritis (overall pain, pain from limb manipulation, and pain after physical exertion).
View complete article: PDF  |  Full-text  | Digital
 
 


Editorial Board Members Related to pharmaceuticals

KAZI MOHSIN

Assistant Professor
Department of Pharmaceutics
King Saud University
Saudi Arabia

Anthony Joseph Berdis

Assistant Professor
Departments of Chemistry and Biology
Cleveland State University
United States

JANAK PADIA

Associate Professor
Center of Biomolecular Therapeutics
University of Maryland
United States

Sarah Hall

Senior Lecturer
Department of Life Sciences
Anglia Ruskin University
United Kingdom

SAJA H. HAMED

Associate Professor
Department of Pharmaceutics and Pharmaceutical Technology
Hashemite University
Jordan

UMA D PALANISAMY

Associate Professor
Department of Biomedical Science
Jeffrey Cheah School of Medicine and Health Sciences
Monash Universtiy
Malaysia

Yi-Wen Liu

Professor
Department of M icrobiology, Immunology and Biopharmaceuticals
National Chiayi University
Taiwan

Natasa Skalko-Basnet

Professor
Department of Pharmacy
University of Tromso
Norway

Jiang He

Associate Professor
Department of Radiology and Medical Imaging
University of Virginia
United States

XIAOYANG QI

Associate Director
Division of Hematology-Oncology
Department of Internal Medicine
University of Cincinnati
United States
Submit Manuscript


Open Access Journals

View All Journals